Progression vs Cyst Stability of Branch-Duct Intraductal Papillary Mucinous Neoplasms After Observation and Surgery.
Journal
JAMA surgery
ISSN: 2168-6262
Titre abrégé: JAMA Surg
Pays: United States
ID NLM: 101589553
Informations de publication
Date de publication:
01 07 2021
01 07 2021
Historique:
pubmed:
20
5
2021
medline:
28
1
2022
entrez:
19
5
2021
Statut:
ppublish
Résumé
The progression of intraductal papillary mucinous neoplasms (IPMNs) of the pancreas to malignant disease is still poorly understood. Observational and surgical series have failed to provide comprehensive information. To identify dynamic variables associated with the development of malignant neoplasms by combining pathological features with data from preoperative repeated observations. The Crossover Observational Multicentric Study included a retrospective cohort of patients with branch-duct IPMNs (BD IPMNs) enrolled in a surveillance program from January 1, 2000, to December 31, 2019. Patients were enrolled from 5 referral centers: the Pancreas Institute, Verona, Italy; Seoul National University Hospital, Seoul, South Korea; Singapore General Hospital, Singapore; Johns Hopkins School of Medicine, Baltimore, Maryland; and University of Texas MD Anderson Cancer Center, Houston. Patients underwent a minimum of 12 months of preoperative surveillance (median, 37 [interquartile range (IQR), 20-68] months). Dynamic variables associated with malignant disease were explored to estimate the presence of high-grade dysplasia (HGD) and invasive cancer at final pathological examination. A total of 292 patients were included in the analysis (137 women [46.9%] and 155 men [53.1%]; median age, 64 [IQR, 56-71] years). During surveillance, 27 patients (9.2%) developed a worrisome feature after 5 years, and 46 of 276 (16.7%) developed high-risk stigmata (HRS). At final pathological evaluation, 107 patients (36.6%) had HGD or invasive cancer, and 16 (5.5%) had IPMNs with concomitant pancreatic ductal adenocarcinoma. Rates of HGD and invasive cancer at pathological evaluation significantly differed between those without worrisome features and those developing HRS from a previous worrisome feature (9 [27.3%] vs 13 [61.9%]; P < .001). Developing an additional worrisome feature during surveillance (odds ratio [OR], 3.24 [95% CI, 1.38-7.60]; P = .007) or an HRS from a baseline worrisome feature (OR, 2.87 [95% CI, 1.01-8.17]; P = .048) was associated with HGD at final pathological evaluation. Among HRS, development of jaundice on a low-risk cyst was independently associated with invasive cancer (OR, 16.04 [95% CI, 2.94-87.40]; P = .001). These findings suggest that in BD IPMNs under surveillance, harboring a stable worrisome feature carries the lowest risk of malignant disease. Development of additional worrisome features or HRS is associated with the presence of HGD, whereas the occurrence of jaundice is associated with invasive cancer.
Identifiants
pubmed: 34009303
pii: 2780040
doi: 10.1001/jamasurg.2021.1802
pmc: PMC8135059
doi:
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
654-661Commentaires et corrections
Type : CommentIn
Références
Ann Surg. 2017 Sep;266(3):536-544
pubmed: 28657939
Pancreatology. 2020 Jul;20(5):895-901
pubmed: 32624417
Gastroenterology. 2018 Feb;154(3):576-584
pubmed: 29074452
Pancreas. 2018 May/Jun;47(5):544-550
pubmed: 29702531
Pancreas. 2017 Oct;46(9):1098-1110
pubmed: 28902778
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Ann Surg Oncol. 2017 Apr;24(4):1120-1126
pubmed: 27822633
Pancreatology. 2010;10(2-3):144-50
pubmed: 20484954
Gastroenterology. 2017 Nov;153(5):1284-1294.e1
pubmed: 28739282
Am J Surg Pathol. 2015 Dec;39(12):1730-41
pubmed: 26559377
Ann Surg. 2020 Dec;272(6):1118-1124
pubmed: 30672797
Gut. 2020 Jan;69(1):7-17
pubmed: 31672839
Dig Surg. 2018;35(6):508-513
pubmed: 29232660
Surgery. 2012 Sep;152(3 Suppl 1):S135-42
pubmed: 22766364
Clin Gastroenterol Hepatol. 2016 Apr;14(4):585-593.e3
pubmed: 26370569
Pancreatology. 2017 Sep - Oct;17(5):738-753
pubmed: 28735806
Ann Surg. 2016 Jan;263(1):162-77
pubmed: 25775066
Ann Surg Oncol. 2018 Jun;25(6):1746-1751
pubmed: 29560572
Surgery. 2018 Dec;164(6):1178-1184
pubmed: 30170819
Gut. 2018 May;67(5):789-804
pubmed: 29574408
Br J Surg. 2018 Dec;105(13):1825-1834
pubmed: 30106195
Am J Gastroenterol. 2019 Oct;114(10):1678-1684
pubmed: 31449158
Gastroenterology. 2015 Apr;148(4):819-22; quize12-3
pubmed: 25805375
Pancreas. 2010 Mar;39(2):232-6
pubmed: 19752768
BJS Open. 2019 Jul 02;3(5):656-665
pubmed: 31592073
J Surg Res. 2018 Nov;231:195-200
pubmed: 30278929
Curr Probl Surg. 2021 Jun;58(6):100879
pubmed: 34144739
Gastroenterology. 2020 Jan;158(1):226-237.e5
pubmed: 31473224